Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

M Maio, A Scherpereel, L Calabro, Joachim Aerts, SC Perez, A Bearz, K Nackaerts, DA Fennell, D Kowalski, AS Tsao, P Taylor, F Grosso, SJ Antonia, AK Nowak, M Taboada, M Puglisi, PK Stockman, HL Kindler

Research output: Contribution to journalArticleAcademicpeer-review

254 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1261-1273
Number of pages13
JournalLancet Oncology
Volume18
Issue number9
DOIs
Publication statusPublished - 2017

Cite this